cant difference (67 vs. 74%, p = 0.129). Conclusions: MRI is valuable for the assessment of MRF. The most appropriate definition of MRF+ in MRI is ≤ 1 mm. The effectiveness is higher in patients who did not undergo neo-ChRT.
Introduction
Since it was first put forward by Heald et al. [1] in 1982, total mesorectal excision (TME) has been used as the standard procedure to treat mid-low rectal cancers with significant local recurrence rate [2] [3] [4] [5] [6] . However, some studies revealed an unfavorable local recurrence rate after standardized TME procedures in a small population of patients. Further studies [7, 8] suggested that preoperative mesorectal fascia involvement (MRF+) is an independent risk factor. MRF is defined as the fine linear structure enveloping the mesorectal compartment harboring the rectum perirectal fat [9] , and it is considered to be involved if the distance between the tumor tissue and MRF is ≤ 1 mm in histopathology [10] . A metaanalysis by Nagtegaal and Quirke [11] showed the patients with preoperative MRF+ had higher local recurrence and distant metastasis rate, as well as reduced life expectancy. The main approaches to assess MRF are CT and MRI. Since MRI can achieve better contrast resolution, it is more reliable in the assessment of MRF+ [12, 13] . However, the definition of MRF+ in MRI is still controversial. Three previous meta-analyses have already evaluated the effectiveness of MRI in the assessment of MRF+ for rectal cancer [14] [15] [16] . But in their studies, patients who underwent neoadjuvant chemoradiotherapy (neo-ChRT) were not studied. It is generally accepted that a second MRI scan is helpful to identify a potentially involved MRF after neo-ChRT in patients with locally advanced rectal cancer [9] . So it is also important and necessary to study patients who underwent neo-ChRT. Besides, a clear definition of MRF+ was not given in their studies. Studies with the definition like 'contiguity of tumor and the mesorectal fascial reflection' were also included (see Appendix 2) , which might have influenced the accuracy of outcomes. Based on this, we conducted this meta-analysis to get the most appropriate definition of MRF+ in MRI and to revalue MRI in the assessment of MRF. As far as we know, this is the first meta-analysis to compare the most appropriate definition of MRF+ and to include the influence of neo-ChRT on MRI accuracy in predicting MRF+.
Methods

Criteria for Study Eligibility
Studies were included if they fulfilled the following criteria: (a) histopathology was used as the golden standard, (b) the definition of MRF+ was ≤ 1 mm in histopathology, and ≤ 1, ≤ 2 or 5 mm in MRI, (c) original articles (if data were used in more than one article, only the newest paper was included), and (d) original primary data were available to extract or reconstruct 2 × 2 contingency tables. If not, authors were contacted to request this information.
Studies having any of the following features were not eligible for inclusion: (a) non-English articles, (b) animal experiments, and (c) reports only as abstract, review and lecture.
Literature Search and Data Extraction
A literature search was performed for relevant publications in PubMed, Medline, Embase and Cochrane Central (1.1.1999-30.6.2012). We retrieved 132 studies in PubMed, 249 in Embase and Medline, and 8 in Cochrane Central (see Appendix 1). Reference lists of these retrieved articles were also searched manually to identify relevant studies and 3 studies were identified. By reading abstracts of all these studies independently by two veteran reviewers, a total of 149 studies that may fit the inclusion criteria were identified.
Assessment of Methodological Quality
Quality was assessed using the checklist of Quality Assessment of Diagnostic Accuracy Studies (QUADAS), which is recommended by Cochrane Collaboration [17] . Each quality item was scored as 'yes', 'no' or 'unclear'. Two reviewers independently reviewed the studies to evaluate the 11 different quality indexes of each study. In case of disagreement, it was resolved by discussion or consulting with a third reviewer. According to Whiting et al. [18] , we did not calculate the summary scores because of its problematic interpretation.
Statistical Analysis
In this study, bivariate random effects model [19, 20] was used to generate the summary estimates of sensitivity, specificity, and diagnostic odds ratio (DOR) through Stata software (Stata SE 12). RevMan 5 (Review Manager software 5.0) was used to draw the summary of receiver-operating characteristic (SROC) curves. In covariate analyses, t test was used and the p value was calculated. The pooled sensitivity, specificity and DOR were compared in patients who underwent neo-ChRT (MRI after neo-ChRT vs. histopathology) and who did not (baseline MRI vs. histopathology) when analyzing the influence of neo-ChRT. 
Investigations of Heterogeneity
Results
Literature Search and Selection of Studies
The literature search identified 389 references and a total of 149 full studies were retrieved, of which 14 were considered relevant for this meta-analysis ( fig. 1 ) [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] .
Study Characteristics
A total of 14 studies and 1,600 patients were included in this study ( table 1 ), including 8 prospective, 4 retrospective and 2 undefined studies. Among the 14 studies, 2 did not have neo-ChRT and 12 did. All 14 studies used ≤ 1 mm as the definition of MRF+, but 3 of them [26, 32, 34 ] also used other definitions ( ≤ 2 and ≤ 5 mm). A total of 10 studies and 1,286 patients (636 of whom had neoChRT) were included when discussing the influence of neo-ChRT ( table 2 ) . Four studies [29, [32] [33] [34] were excluded because they were not available to extract or reconstruct 2 × 2 contingency tables of patients who had neo-ChRT and those who did not separately. From table 2 we can see 7 of the 10 included studies had neoChRT and they all had second MRI and were compared with the final histopathology.
Quality Assessment
The quality of included studies is summarized in table 3 . It shows that the main disagreement is in 3 out of the 11 quality indexes (items 1, 3 and 7). In this study, item 1 indicates that studies should include all kinds of rectal cancer including upper, middle, lower and T1-T4 rectal cancers. Only 5 studies met this criterion. Item 3 is defined as follows: if the patient underwent neo-ChRT the surgery should be performed in 5-10 weeks, otherwise the surgery should be performed in 8 weeks after neo-ChRT. Only 6 studies met this criterion. Item 7 indicates that histologists did not know the results of MRI when they were analyzing the specimens. Twelve studies did not describe this practice. 
Data Analysis
From table 4 , we can see the different definitions of MRF+ ( ≤ 1, ≤ 2 and ≤ 5 mm) in MRI exhibited different pooled sensitivity (76, 79 and 92%, respectively), specificity (88, 66 and 48%, respectively) and DOR (22.4, 6.6 and 16.0, respectively). The definition of MRF+ at ≤ 1 mm showed the highest DOR. Table 5 shows the details of each outcome and figure 2 shows each SROC curve when using ≤ 1 mm as the definition of MRF+. Summary estimates of sensitivity, specificity and DOR were produced with 95% confidence interval (CI).
Covariate Analyses
Based on the heterogeneity investigations, we performed covariate analysis of items a, b, e, and i. Though items c, d, j and k also have very important influences on the results, covariate analysis was not performed due to insufficient data.
As shown in table 5 , sensitivity, specificity and DOR of patients who underwent neo-ChRT were 67% (95% CI 43-85%), 88% (95% CI 77-95%) and 15.5 (95% CI 6.5-37.0). The specificity and DOR were much lower (p = 0.026 and 0.001) and the sensitivity showed little difference (p = 0.1286), comparing with the patients who did not undergo neo-ChRT.
The full details of pooled sensitivity, specificity and DOR of the other subgroups are listed in table 5 . The sensitivity, specificity and DOR were all much higher (p ≤ 0.05) when MRI was performed on 1.5-tesla (T) instruments compared with 1.0-T instruments. The type of studies (retrospective vs. prospective) had marked influence on the sensitivity (p ≤ 0.01), but not on the specificity and DOR. Each confidence region has a summary point (dots) which represents the most likely values of true summary sensitivity and specificity. 
Discussion
For the definition of MRF+ in histopathology, ≤ 1 mm was recommended by the National Comprehensive Cancer Network (NCCN) [10] , and this study adopted this definition. There is much debate about the definition of MRF+ in MRI. We consider ≤ 1 mm to be the most appropriate definition in MRI. The reasons are as follows: in the studies of our initial search, there were 4 types of definitions of MRF+ ( ≤ 1, ≤ 2, ≤ 5 mm and no specific distance) (see Appendix 2) and ' ≤ 1 mm' is the most frequently used one. 17 of the articles used ' ≤ 1 mm' as the definition, 14 were included in this study and 3 [35] [36] [37] were excluded due to lack of data. Previous articles showed the distances of the tumor to MRF revealed by MRI and histology was in good agreement [38] [39] [40] . Brown et al. [39] pointed out that specimen fixation or processing had no appreciable effect on the measurement of distance from tumor to MRF. This observation implies the distance of the tumor to MRF measured in MRI and histopathology had little difference. Because the definition of MRF+ in histopathology is ≤ 1 mm [10] , using ≤ 1 mm as the definition of MRF+ in MRI appears to be the most appropriate. Though Beets-Tan et al. [41] found that a tumor-free MRF of at least 1.0 mm can be predicted with a high degree of certainty when the measured distance on MRI is at least 5.0 mm, that difference in distance between MRI and histopathology had already been reduced [22] with consistent use of a high-resolution technique and the improved skills of radiologists. Nowadays, Beets-Tan and colleagues [42] also use ≤ 1 mm for invasion and ≤ 2 mm which they call high risk. In addition, we found that in the 3 subgroups concerning MRF+ ( ≤ 1, ≤ 2 and ≤ 5 mm), ' ≤ 1 mm' group exhibited the highest DOR ( table 4 ) . Recently, a multicenter study suggests that using the definition of ≤ 1 mm did not decrease the accuracy of MRI in predicting MRF status compared with the definition of ≤ 2 mm or even ≤ 5 mm. On the contrary, it would reduce overtreatment that could achieve only minimal gain based on very low [34] 1999 unclear yes unclear yes yes yes unclear yes yes yes yes 1 = Representative spectrum, in this meta-analysis it means tumors from all levels of rectum (upper, mid, low; T1-T4). 2 = Acceptable reference standard. 3 = Acceptable delay between tests, in this meta-analysis it means time period ≤8 weeks between MRI and surgery (≤2 weeks if patient received pre-RCT) [9] . 4 = Partial verification avoided. 5 = Differential verification avoided. 6 = Incorporation avoided. 7 = Index test results blinded. 8 = Reference standard results blinded. 9 = Relevant clinical information. 10 = Uninterruptable results reported. 11 = Withdrawals explained. [24] . For all these discussed reasons, we consider ≤ 1 mm to be the best definition of MRF+ in MRI. From table 4 , we can see the sensitivity, specificity and DOR are 76%, 88% and 22.4, respectively, when we adopt ≤ 1 mm as the definition. It is much lower compared with the results by Al-Sukhni et al. [16] (77%, 94% and 56.1, respectively), which is the latest study and also has the largest amount of patients among the three previous meta-analyses [14] [15] [16] . The following factors could have caused these differences: first, neo-ChRT is probably the most important factor; second, we only included studies that used a definition of MRF+ at ≤ 1 mm both in MRI and histopathology, and third, we have included studies that were published after Al-Sukhni's study [21] [22] [23] [24] .
Al-Sukhni et al. [16] excluded patients who had neoChRT, because they considered neo-ChRT administered after MRI might downstage the tumor so that final histopathology no longer represented an appropriate reference standard for the original MRI. However, we still considered MRI valuable in the assessment of MRF of neoChRT patients for the following reasons: first, when we calculate the influence of neo-ChRT, all studies ( table 2 ) did a second MRI after neo-ChRT and were compared with the final histopathology, thus reducing the differences; second, studies showed that preoperative shortcourse radiotherapy or radiochemotherapy has little influence on MRF+ [11, 43, 44] , and third, not all patients' MRI before neo-ChRT could be gained. In this situation, the MRI after neo-ChRT became the only data we could use. Table 5 shows that the DOR and specificity were much lower when patients had neo-ChRT, because there was much fibrosis and tumor 'scar', which made it difficult to distinguish from treated tumor [29, 30, 32] . Studies show that MRI using diffusion-weighted imaging (DWI) can increase the accuracy in patients who had neo-ChRT. One of the reasons is that DWI provides information that reflects tissue cellularity and the integrity of cellular membranes and it is sensitive to intratumoral changes induced by chemoradiation therapy, so it is easier to discriminate between fibrosis and residual tumor [45] [46] [47] [48] [49] [50] [51] . Park et al. [46] showed that the accuracy improved from 0.4 (0.69 in observer 2) to 0.89 (0.93 in observer 2). In our 14 included studies, only 1 used DWI ( table 1 ), so we did not analyze the influence of using DWI.
Apart from DWI, other instruments of MRI can also influence the estimates of MRI, especially the different magnetic strength (T). Al-Sukhni et al. [16] found 3.0 T MRI had much higher specificity than 1.0 or 1.5 T on T staging, but Maas et al. [52] showed no difference between 3 and 1.5 T MRI for the T staging. In our analysis, [27] has the highest accuracy and the other [25] has the lowest accuracy. b Blomqvist et al. [34] : MRI scan was performed on the specimen (in vitro) in this study.
c Studies used 1.5 T: the studies which used 1.5 T of MRI in all patients (7 studies, details in table 1). d Studies used lymph node: studies in which metastatic lymph node was used for measuring the closest distance to the MRF (6 studies, details in table  1 ).
e Sensitivity, specificity and DOR were calculated by comparing MRI after neo-ChRT with histopathology. f Sensitivity, specificity and DOR were calculated by comparing baseline MRI with histopathology.
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Dig Surg 2014;31:123-134 DOI: 10.1159/000363075 129 no study used the 3.0 T MRI, but the 1.5 T MRI showed higher sensitivity, specificity and DOR than 1.0 T MRI ( table 5 ) . But it was influenced by considerable heterogeneity caused by neo-ChRT, the use of DWI and the individual differences of radiologists and surgeons. So, RCT studies with larger samples are needed to establish the influence of different tesla.
The location of tumor is also an important factor that can influence the accuracy of MRI for the assessment of MRF. Studies found that MRI had lower accuracy to assess MRF in anterior tumors than in posterior tumors [25, 30, 52] . The anterior perirectal fat is usually very thin, which makes it more difficult to delimit the anterior MRF or Denonvilliers' fascia in MRI. Besides, it is less reliable to predict MRF in lower rectal tumor than in middle and upper rectal tumors by MRI because lower rectal tumor is much closer to the horizontal position and anteriorly closer to the seminal vesicles in male patients and to the posterior vaginal wall in female patients. Glimelius et al. [53] proposed that in low tumors that are below the levator muscles, where the MRF cannot be defined, the relationship to the sphincters should be described. In our meta-analysis, the proportions of tumors arising from different locations were varied among each article ( table 1 ). Due to lack of data we did not perform a detailed analysis. This may be one limitation of our study. Recently, in order to enhance the accuracy of MRI in staging low rectal cancer, some studies proposed a novel MRI staging technique, which was based on the relationship of the tumor to the levators and individual components of the sphincter complex [53] [54] [55] . However, the benefit of the new staging technique is not clear and larger prospective studies are needed to confirm its benefit.
There are other factors affecting the accuracy of MRI for the assessment of MRF, such as the tumor stage and the histological type of tumor. Kim and colleagues [56] found T3 tumor was related to the incorrect prediction of MRF. Different types of tumor can also influence the accuracy. Studies showed mutinous tumors would increase the error for the assessment of MRF in neo-ChRT patients, because mutinous tumors had higher signal intensity after chemoradiation therapy than non-mutinous tumors, which made it difficult to differentiate residual tumor from inactive mucin pools [38, 40] .
According to NCCN, the definition of MRF+ in histopathology includes both secondary to metastatic lymph node and direct tumor extension [10] . In the 14 included studies, only 6 [23, 26, 28, 30, 32, 33] gave a positive instruction on whether metastatic lymph node was used for measuring the closest distance to MRF ( table 1 ) . This may be another limitation of our study. We analyzed these 6 studies and found that they had a lower sensitivity and higher specificity when MRF is positive and when metastatic lymph node was present ( table 5 ) .
There are several other limitations in our study. First and also the most important one is the bias coursed by the quality of surgery. Quirke et al. [57] found that surgery was achieved in the mesorectal plane in only 52% patients (34% in intramesorectal plane and 13% in muscularis propria plane), and the ratio was lower in abdominoperineal excision compared with anterior resection, but similar in primary surgery and surgery after neo-ChRT. Besides, Martling et al. [33] thought that the surgeon was aware of the findings on preoperative MRI, which may have influenced the surgical approach, thus leading to extended resection in patients with a predicted involved MRF. These non-standard TME surgeries with extended or contracted resection reduce the accuracy of MRI. Second, we restricted our search to the studies published in English, which may lead to language bias. Third, 3 studies [35] [36] [37] that could not be used to extract or reconstruct 2 × 2 contingency tables were excluded. The exclusion of these data may influence our results. Fourth, in our study, the time interval between second MRI and surgery was different ( table 2 ) , and as we know, changes in disease status can occur in this time frame [58] . However, van der Paardt et al. [59] described a group with a maximum 6-week interval between second MRI and surgery, and found that they had a difference but which was not statistically significant. So in our opinion, the different time intervals were another source of bias, but during a certain time frame. How to clearly define this interval and its relationship with the results needs further investigation. Fifth, considerable heterogeneity was observed in this meta-analysis and did not appear to diminish when the 2 studies with lowest and highest accuracy were excluded. The heterogeneity was probably caused by variations in study design, patient characteristics, different MRI parameters, and the individual differences of radiologists, surgeons and pathologists.
In conclusion, MRI has a favorable specificity in the assessment of preoperative MRF for rectal cancer, but its sensitivity remains to be further investigated. Our metaanalysis found that the definition of ≤ 1 mm is the most appropriate in MRI, and neo-ChRT has marked influence on the effectiveness of MRI in assessing MRF. 
